COMP <GO>
CLBT vs NVDA // RETURN ON INVESTED CAPITAL (ROIC)
Cellebrite DI Ltd. (NASDAQ) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: CLBT 4
— NVDA 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: NVDA
LAST: $12.28 (+3.02%) • MKT CAP: $3.09B
roic
14.60%
LAST: $213.66 (-0.80%) • MKT CAP: $5.15T
roic
65.06%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLBT VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLBT | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 84.20% | 74.67% | +9.53 | CLBT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 14.60% | 65.06% | -50.46 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 38.1x | 23.2x | +14.89 | NVDA | /valuation <GO> |
| Free Cash Flow Yield | 5.19% | 2.58% | +2.61 | CLBT | /fcf-yield <GO> |
| Operating Margin | 14.00% | 65.21% | -51.21 | NVDA | /operating-margins <GO> |
| Net Profit Margin | 16.50% | 63.66% | -47.16 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) | 18.60% | 83.38% | -64.78 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.02% | -0.02 | NVDA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.95 | 19.52 | -14.57 | NVDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CLBT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 9.01% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.1 | 51.1 | +7.02 | CLBT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 2.04 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.1x | 17.0x | +16.08 | NVDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.09B | $5.15T | -$5.15T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLBT REV | NVDA REV | CLBT GROSS % | NVDA GROSS % | CLBT FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $475.7M | $130.50B | 84.2% | 75.0% | $160.3M | $60.85B |
| FY 2024 | $401.2M | $60.92B | 84.4% | 72.7% | $123.6M | $27.02B |
| FY 2023 | $325.1M | $26.97B | — | 56.9% | $102.1M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLBT // BETA —
NVDA // BETA 2.04